a $6 billion biosimilar opportunity
Published 6 years ago • 1.2K plays • Length 5:15Download video MP4
Download video MP3
Similar videos
-
7:48
welcome to the next drugs the future for biosimilars
-
8:05
biocon-mylan’s biosimilar for cancer drug pegfilgrastim gets u.s. fda nod
-
3:02
biosimilar medications — what patients need to know
-
1:57
biocon rallies on fda's letter on mylan's biosimilar
-
3:07
the promise of biosimilars
-
2:21
what are biosimilars?
-
6:07
manufacturing of biologics
-
2:52
how biologic medicines are made | how it's made
-
3:18
what is a biosimilar, exactly?
-
12:26
biocon's kiran shaw on biosimilars space
-
15:01
euronews debates highlights | how can europe shape the future of biosimilar medicines?
-
1:25
what is a biosimilar?
-
1:58
biosimilars: opportunities, challenges and the future for a sustainable global market
-
3:00
biosimilars: complex copycat drugs
-
3:33
biosimilars: manufacturing and inherent variation
-
1:03:55
panel discussion: biologics and biosimilars - challenges and opportunities in fdd
-
1:10
pfizer becomes major player in biosimilar market
-
5:20
data requirements for biosimilars
-
4:04
looking into the rich biosimilar landscape with cate lockhart of bbcic
-
3:40
biosimilar medicines, an opportunity for healthcare
-
1:42
biosimilars vs. interchangeable biosimilars: what’s the difference?
-
57:53
biosimilars: what you need to know